SCHEMBL3740150

SCHEMBL3740150

CC(C)Oc1ccc(-c2noc(-c3ccc(NC(=O)OC(C)(C)C)cc3)n2)cc1Cl

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 4/20 0.60
MINK1 Q8N4C8 4/20 0.60
DYRK3 O43781 2/20 0.60
MARK3 P27448 2/20 0.60
PLK1 P53350 2/20 0.60
MAP4K5 Q9Y4K4 2/20 0.60
PRKCD Q05655 1/20 0.55
S1PR1 P21453 14/20 0.52
S1PR3 Q99500 5/20 0.50
HPGD P15428 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
MEN1 O00255 1/20 0.49
LMNA P02545 1/20 0.49
KMT2A Q03164 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
S1PR5 Q9H228 1/20 0.49
KDM4E B2RXH2 1/20 0.48
NPC1 O15118 1/20 0.48
ADRB2 P07550 1/20 0.48
MAPT P10636 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1965824 0.86 MAP4K4 (0.58) MAP4K4MINK1DYRK3MARK3PLK1
SCHEMBL1965673 0.84 MAP4K4 (0.56) MAP4K4MINK1DYRK3MARK3PLK1
SCHEMBL1967320 0.83 SMN1; SMN2 (0.69) MAP4K4MINK1DYRK3MARK3PLK1
SCHEMBL12582033 0.81 MAP4K4 (0.62) MAP4K4MINK1DYRK3MARK3PLK1
SCHEMBL12582080 0.81 MAP4K4 (0.56) MAP4K4MINK1DYRK3MARK3PLK1
SCHEMBL3746333 0.80 MAP4K4 (0.63) MAP4K4MINK1DYRK3MARK3PLK1
SCHEMBL3741047 0.80 S1PR1 (0.73) MAP4K4MINK1DYRK3MARK3PLK1
SCHEMBL1965506 0.80 MAP4K4 (0.59) MAP4K4MINK1DYRK3MARK3PLK1
SCHEMBL12162495 0.80 MAP4K4 (0.56) MAP4K4MINK1DYRK3MARK3PLK1
SCHEMBL1965051 0.79 MAP4K4 (0.52) MAP4K4MINK1DYRK3MARK3PLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7834039-B2 Oxadiazole compounds ABBOTT LABORATORIES (US) 2010-11-16 US disclosed
US-7834039-B2 Oxadiazole compounds ABBOTT LABORATORIES (US) 2010-11-16 US disclosed
US-7834039-B2 Oxadiazole compounds ABBOTT LABORATORIES (US) 2010-11-16 US disclosed
EP-2109364-A1 NOVEL OXADIAZOLE COMPOUNDS Abbott Laboratories (US) 2009-10-21 EP disclosed
US-20080280876-A1 Novel oxadiazole compounds ABBVIE INC. 2008-11-13 US disclosed
US-20080280876-A1 Novel oxadiazole compounds ABBVIE INC. 2008-11-13 US disclosed
US-20080280876-A1 Novel oxadiazole compounds ABBVIE INC. 2008-11-13 US disclosed
WO-2008076356-A1 NOVEL OXADIAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280876-A1 Novel oxadiazole compounds S1PR3, S1PR1, S1PR2 MAP4K4 2535/4885MINK1 1243/4885DYRK3 2951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.